ArticleDisease markers2018
Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer.
Article in Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- A systematic review and Bayesian meta-analysis assessing intelectin-1 in cancer patients and healthy individuals.Frontiers in oncology · 2024Pooled it
- Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Appetite-regulating hormones-leptin, adiponectin and ghrelin-and the development of prostate cancer: a systematic review and exploratory meta-analysis.Prostate cancer and prostatic diseases · 2020Pooled it
- Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms.Current obesity reports · 2025Review
- High Intelectin-1 Expression Associated with Aggressive Tumor Behavior and Worse Survival in Rectal Cancer.OncoTargets and therapy · 2025Article
- Evaluate the Serum of Irisin, Omentin-1, and Oxidative Status in Males with Prostatic Cancer.Reports of biochemistry & molecular biology · 2024Article
- Review
- Potential Value of Visfatin, Omentin-1, Nesfatin-1 and Apelin in Renal Cell Carcinoma (RCC): A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Review
- Review
- The Emerging Role of Intelectin-1 in Cancer.Frontiers in oncology · 2022Review
- Integrating inflammatory serum biomarkers into a risk calculator for prostate cancer detection.Scientific reports · 2021Article
- Serum Levels of Irisin and Omentin-1 in Breast Neoplasms and Their Association with Tumor Histology.International journal of endocrinology · 2021Article
- Inflammatory risk factors for hypertriglyceridemia in patients with severe influenza.The Journal of international medical research · 2020Article
- Assessment of expression levels of leptin and leptin receptor as potential biomarkers for risk of prostate cancer development and aggressiveness.Cancer medicine · 2020Article
- Serum Omentin Levels in Patients with Prostate Cancer and Associations with Sex Steroids and Metabolic Syndrome.Journal of clinical medicine · 2020Article
- Can the Irisin be a Biomarker for Prostate Cancer? A Case Control Study.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review.Cancer management and research · 2020Review
- Clinical and Genetic Predictors of Priapism in Sickle Cell Disease: Results from the Recipient Epidemiology and Donor Evaluation Study III Brazil Cohort Study.The journal of sexual medicine · 2019Article
- Anti-Cancer Effects of Green Tea Polyphenols Against Prostate Cancer.Molecules (Basel, Switzerland) · 2019Review
- Altered circulating levels of adipokine omentin-1 in patients with prostate cancer.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) is the first in terms of occurrence in Europe and second in Poland. The PCa risk factors include: genetic load, obesity, diet rich in fat, hypertriglyceridemia, and exposure to androgens. The prostate-specific antigen (PSA) level may be elevated in prostate cancer or other prostate disorders. Fat tissue secretes adipocytokines, which increase the risk of cancer development and metastasis.
objectivesThe aims of the study were to investigate the relationship between circulating levels of PSA, adipocytokines: omentin, leptin, hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF) in serum obtained from patients with benign prostate hyperplasia (BPH) and prostate cancer (PCa).
methodsForty patients diagnosed with BPH and forty diagnosed with PCa were assessed for the purpose of the study. The concentrations of omentin, leptin, HGF, and VEGF were determined using enzyme-linked immunosorbent assays (EIA).
resultsPSA level was significantly higher in the PCa group than in BPH (18.2 versus 9 ng/mL,
conclusionsPSA level as well as the level of omentin may be valuable markers of PCa with clinical significance, when compared to PSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.